HUGEN alumnus Dan Handley appointed to drug discovery board of directors


GLOBE NEWSWIRE - Predictive Oncology Inc., an AI-driven discovery services company providing predictive models of tumor drug response to improve clinical outcomes for patients, today announced the unanimous appointment of doctoral alumnus Daniel Handley (HUGEN '08) to its Board of Directors.  Handley serves as professor and director of the Clinical and Translational Genome Research Institute at the Southern California University of Health Sciences. A decorated U.S. Navy veteran, he completed post-doctoral training at Magee-Women’s Research Institute researching advanced genomic technologies applied to fetal and maternal health.  

“Predictive Oncology is once again very fortunate to announce another exemplary addition to our Board of Directors. Dan has a varied and strong background,” said Dr. Carl Schwartz, CEO of Predictive Oncology, “I greatly anticipate working with Dan and benefitting from his knowledge and experience.”

Find out more


Search for an Article